Metformin for Metabolic Syndrome
This study is evaluating whether metformin is more effective than placebo in treating prostate cancer.
See full descriptionAbout the trial for Metabolic Syndrome
Treatment Groups
This trial involves 2 different treatments. Metformin is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
About The Treatment
Side Effect Profile for Vildagliptin (LAF237)
Eligibility
This trial is for male patients aged 18 and older. You must have received newly diagnosed for Metabolic Syndrome or one of the other 3 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Metformin will improve 1 primary outcome, 10 secondary outcomes, and 19 other outcomes in patients with Metabolic Syndrome. Measurement will happen over the course of 9 months.
Patient Q & A Section
Can metabolic syndrome be cured?
With good treatment, symptoms can be eliminated, and metabolic abnormalities can be practically eliminated. However, there is no guarantee that they will not come back. Obesity is the only important risk factor for MetS that is not completely curable.
How many people get metabolic syndrome a year in the United States?
The prevalence of MetS is high in the United States, even among those 30-34 year olds who are asymptomatic. The number of those affected by the MetS is not clear. To know which groups are at the greatest risk is indispensable to the development of preventive and therapeutic interventions.
What are common treatments for metabolic syndrome?
Clinicians should have a good understanding of the underlying causes of insulin resistance in a patient with metabolic syndrome to select the best treatment. Clinicians need to be aware that some people will be responsive to statin therapy. However, statins are not effective in all patients with the metabolic syndrome. For patients not benefiting from statins, ezetimibe therapy offers reasonable improvement in blood lipid levels. Weight loss is effective in improving the lipid profiles in patients with metabolic syndrome, but there is a high risk that dieting will be ineffective due to the high adherence rate to dieting in the metabolic syndrome patient cohort. Weight loss and a reduction in the waist-to-hip ratio are key variables for preventing metabolic syndrome.
What is metabolic syndrome?
Metabolic syndrome seems to be one of the common complications among the patients with Type 2 diabetes, and they can exhibit a series of cardiovascular diseases, such as stroke, myocardial infarction, peripheral arterial disease, and non-cardiac vascular disease, which seems to be related to insulin resistance.
What are the signs of metabolic syndrome?
Metabolic syndrome is diagnosed when three of the following five criteria are met: 1) waist circumference > or = 5 x the 95th percentile ; 2) fasting plasma glucose > or = 6.1 mmol/L ; 3) triglycerides > or = 2.7 mmol/L ; 4) HDL cholesterol < 1.0 mmol/L ; and 5) blood pressure > or = systolic 140 mmHg or diastolic 90 mmHg. There is no specific medical test that can predict the development of diabetes or cardiovascular disease (CVD). However, if the patient fulfills 3 of the following criteria during a 5- yr follow-up period, they have a greater than 10% incidence of diabetes and CVD.
What causes metabolic syndrome?
Most people with metabolic syndrome have an underlying disorder, even if their symptoms are limited. The symptoms of metabolic syndrome are often the result of underlying pathophysiology, but many people with symptoms of metabolic syndrome have normal biochemistry and imaging tests, and no identifiable underlying condition. When metabolic syndrome is associated with a specific underlying disorder the syndrome is said to have a 'genetical' or known pathophysiology.
How does metformin work?
These data underscore the need for further investigation of the impact of metformin on insulin resistance and the metabolic control of non-diabetic patients with MS.
Have there been other clinical trials involving metformin?
Recent findings of the present trial suggest that metformin does not appear to increase the risk of pregnancy loss at least in women without previous pregnancy loss on account of a previous gestational diabetes mellitus diagnosis. Further meta-analysis of prospective controlled trials is warranted to confirm these results.
What are the chances of developing metabolic syndrome?
The probability that someone with MetS develops a clinical heart attack or stroke during a 10-year period varies widely. Overall, MetS does not substantially increase the chance of these events.
What is the latest research for metabolic syndrome?
The latest research indicates that the metabolic syndrome and insulin resistance are related to the risks of developing various types of cancers, cardiovascular diseases, and mental illnesses. The metabolic syndrome also increases the risk of developing chronic kidney disease, and the risk of developing Alzheimer's disease.
Does metformin improve quality of life for those with metabolic syndrome?
Metformin, when started at a moderate dose, improves quality of life for people with overweight/obesity and metabolic syndrome. However, people with higher HbA1c levels may not benefit from metformin. Future studies should investigate whether a higher dose of metformin may be advisable for patients with low dietary intake (hypophagic patients).
How quickly does metabolic syndrome spread?
The prevalence of MetS in the entire study population began to increase from 2003 until 2006. Interestingly, there was no evidence that the prevalence changed significantly between 2006 and 2008, suggesting the persistence of the MetS. We also found that a higher percentage of MetS in 2009 was associated with poorer self-rated health, irrespective of whether the patient was currently receiving statin treatment.